AI

Recursion Pharmaceuticals $121 million Series C for AI drug discovery

Recursion Pharmceuticals has closed a $121 million Series C funding round, led by Scottish Mortgage Investment Trust, with participation from new and all prior institutional investors.

The funds will be invested to continue building Recursion's AI-enabled drug discovery platform, as well as to develop capabilities to accelerate new chemical entity chemistry and predict safety pharmacology.

Webit 2019 Health Summit roundup

There isn't any aspect of healthcare that isn't being transformed by technology. The health-related technologies on display reflected the work that is being done to prevent illness, to deliver more effective treatments, and to reduce the growing cost of healthcare.

Global collaboration publishes recommendations to speed rare disease diagnosis

The Global Commission to End the Diagnostic Odyssey for Children has today published recommendations on how to solve the challenge of diagnosing rare diseases. The commission was set up by Takeda, Microsoft, and EURORDIS-Rare Diseases Europe to find solutions to core barriers preventing timely diagnosis for rare diseases.

HIMSS19 focus on value-based care

At HIMSS19, one theme seems to filter through all the buzz and activity: delivering value-based, patient-centred care.